Panhematin provides a therapeutic benefit in experimental pancreatitis.

ABSTRACT:

Background and aim

Acute pancreatitis (AP) can result in pancreatic necrosis and inflammation, with subsequent multi-organ failure. AP is associated with increased neutrophil recruitment and a rise in pro-inflammatory cytokines such as TNFα. Pretreatment with haemin, results in recruitment of haem-oxygenase-1 (HO-1)(+) macrophages and protects against experimental pancreatitis. It is not clear whether modulation of HO-1 after onset of disease has a protective role. In this study, we tested the utility of Panhematin, a water-soluble haemin formulation, in activating and inducing pancreatic HO-1, and as a therapeutic agent in treating mouse acute pancreatitis.

Methods

We defined the distribution of radiolabelled haemin, then used in vivo HO-1-luciferase bioluminescence imaging

SUBMITTER: Habtezion A 

PROVIDER: S-EPMC3580958 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature